Early chromosome changes a potential target in triple-negative breast cancer

Breast cancer cells

MD Anderson scientists found that chromosomal changes in triple-negative breast cancer occur early on and in short “bursts,” contradicting the long-standing belief that they occur slowly over time in many cancers. This could lead to more effective diagnostic and treatment strategies for triple-negative breast cancer.

The team used highly multiplexed single-nucleus sequencing to delve into the clonal substructure and evolution of CNAs in 12 triple-negative breast cancer patients who had had their tumors surgically removed ahead of further therapy. With this new sequencing method, they were able to sequence the genomes of individual tumor cells and study numerous cells simultaneously.

“The current model asserts [DNA copy number aberrations, or CNAs] are acquired gradually and sequentially over extended periods of time, leading to successively more malignant stages of cancer,” said Nicholas Navin, a professor of genetics at the MD Anderson Cancer Center, in a statement. “Another model is punctuated evolution in which CNAs are acquired in short bursts of crisis, followed by stable clonal expansion that form the tumor mass. Our study suggests punctuated copy number evolution is common in TNBC patients.”

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

Previous genomic studies have focused on a snapshot in time, after the tumor has been removed, the researchers said in the statement. Therefore, it has been challenging to examine the history of how chromosomes evolve in cancer.

And the “bursts” may have applications beyond triple-negative breast cancer. “Our preliminary data in cancers such as prostate, colon, liver and lung suggest a punctuated model of copy number evolution is also likely to be operative in other solid cancers,” Navin said. “This model has important implications for our evolutionary understanding of cancer growth dynamics and for the clinical diagnosis and treatment of TNBC patients.”

- here's the statement
- and here's the abstract

Related Articles:
Mayo Clinic researchers draw connection between microbiome and cancer from the same human breast tissue
Existing drug could prevent BRCA1-positive breast cancer
Scientists uncover new target for triple-negative breast cancer

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.